MyReceptivaTM Test Information

Learn more about the test, successful collection procedures and how to understand your results.

Frequently Asked Questions

The MyReceptivaTM Test is a proven and powerful tool for the detection of endometriosis using a protein marker called BCL6. The test was developed and patented by researchers at the University of North Carolina at Chapel Hill and originally licensed by Cicero Diagnostics for endometriosis detection for women with fertility issues in October of 2016.

BCL6 plays a complex role in the pathogenesis of endometriosis, affecting multiple aspects of the disease, including cell growth, survival, inflammation, and immune response. BCL6 is expressed in high levels on the uterine lining in over 90% of the cases in women with endometriosis (both symptomatic and asymptomatic). BCL6 is not typically detected on the uterine lining in women with normal endometrial tissue.

Cicero Diagnostics offers the same pricing for all patients, regardless of insurance status. This keeps pricing lower and accessible for all. If you do have insurance, you will be provided with a detailed receipt that can be used for self-submission. Others will have the opportunity to seek reimbursement via their flexible healthcare spending accounts. Cicero Diagnostics does not bill or contract with insurance plans.

Laparoscopy remains the gold standard for endometriosis diagnosis due to the  direct visual capability of a scope. However, due to the cost of surgery and the difficulty some women experience in accessing skilled surgical healthcare, the MyReceptivaTM test was developed to provide the highest detection accuracy available. With a detection rate greater than 90%, the MyReceptivaTM test is one of the first detection tools to reliably predict women that would most benefit from surgery.  If not interested or ready for surgery, the MyReceptivaTM test can help identify patients that would most benefit from the various medications now available to alleviate pain and symptoms associated with endometriosis while at the same time providing women knowledge of a disease that can affect future fertility decisions.

Endometriosis surgeons support the use of MyReceptivaTM testing because of its high accuracy.  Multiple independent studies by endometriosis surgeons have shown an over 90% concordance between positive MyReceptivaTM results and subsequent laparoscopic findings of endometriosis or other inflammatory conditions. This allows for faster diagnosis and more effective treatment options. The ability to refer the proper patients to the right specialist is the key to reducing the time to diagnosis of endometriosis, which currently is 7-10 years!

There are no other proven laboratory tests for the detection of endometriosis. The use of ultrasound and other technologies are being offered in some healthcare settings but have severe limitations in their abilities to detect or visualize all forms of
endometriosis. Except for diagnostic laparoscopy, no detection methods are currently offered that can provide greater than 90% detection rates for endometriosis.

Physicians such as Obstetricians (OBs) are just learning about MyReceptivaTM and its powerful ability to detect endometriosis via uterine inflammation. To help you engage with your physician about MyReceptivaTM testing, please review the downloadable information we provide on this website to share with your provider in advance of your biopsy visit.

If your doctor is reluctant to perform the biopsy, please contact us for further assistance. Cicero Diagnostics can offer support in multiple ways by providing your physician’s office with the most updated information on testing or by helping you find another local provider to perform the biopsy.

ReceptivaDx™ is the original test first introduced to the fertility market back in 2017. The ReceptivaDx™ test is used exclusively for women going through IVF and provides answers to fertility specialists for women that are experiencing IVF failure and/or
pregnancy loss following an IVF transfer.

The MyReceptiva™ test is a cost-effective and more widely available version of the
ReceptivaDx test. In addition to helping women with fertility challenges that are not
working with an IVF center and/or do not plan to seek advanced fertility assistance, the
MyReceptiva™ test is now being offered to assist in early detection of endometriosis in
non-fertility patients.

MyReceptiva™ offers a qualitative result (positive or negative) that indicates the
likelihood of endometriosis being present. The MyReceptiva™ test shares the same
level of accuracy as the ReceptivaDx test. The MyReceptiva TM  test is $585 US vs $690
US for the quantitative ReceptivaDx test. The difference in cost is related to the
expanded result information provided to IVF specialists on whether to treat patients
before proceeding with an IVF transfer.

During a routine office visit, a thin catheter (compared to a spaghetti noodle in diameter) is gently inserted thru the vaginal canal, then passed through the cervix into your uterus. Placed against your uterine lining, a suction-like technique is used to pull cells from the uterine lining into the tube. You will experience temporary discomfort and possibly some light cramping in the 5-10 minutes following the procedure. Most patients can resume normal daily activities within 15-20 minutes after a brief resting period. The sample is collected into a vial with preservative and then shipped overnight to our lab location.

Endometrial biopsies are collected during a routine office visit and can be done by any women’s healthcare specialist with the proper training. Your Ob-Gyn office can easily assist with the taking of this biopsy. Biopsy collection information is available for download below to share with your healthcare professional. This same information is available on our MyReceptivaTM App and will also be provided in the MyReceptivaTM Collection Kit.

Per healthcare guidelines, MyReceptivaTM test results are communicated back to your physician within 7-10 business days. Although results are sometimes available sooner, your office needs time to review and chart results before contacting you.

Talk To Your Healthcare Provider

To help you speak with your healthcare provider about MyReceptivaTM testing, please download this document and bring it with you on your next visit.

Prepare for your visit

Understanding Your Results

Identifying uterine lining inflammation is the most powerful tool available for the detection of endometriosis. Only laparoscopic surgery to diagnose endometriosis has been proven to be more effective.

Positive result

BCL6 Positive Result

If your BCL6 results are positive, you have a 90% or greater chance that endometriosis is present and confirmable via laparoscopy.*

A positive MyReceptivaTM result indicates the likelihood that endometriosis will be found via surgery. The positive result helps justify the need for surgery in patients with previously undiagnosed pain. For women with fertility issues, various treatment options such as hormone suppression can also be considered to provide new pathways to pregnancy.

negative result

BCL6 Negative Result

If your BCL6 results are negative, you have less than 7% chance that endometriosis will be found via laparoscopy.

A negative MyReceptivaTM test result provides assurance that endometriosis is unlikely to be the cause of undiagnosed pain. For fertility patients, a negative result provides assurance that the uterine lining is receptive and not the likely cause of fertility issues.

Please note: The MyReceptivaTM test is a detection tool and should not be used for diagnostic confirmation. The test detects the presence of the BCL6 protein, a marker of inflammation proven to be highly associated with endometriosis. Providers are encouraged to refer patients for further evaluation to a qualified gynecologic surgeon specializing in endometriosis.

*References: 1. Endometrial BCL6 overexpression in Eutopic endometrium of women with endometriosis, Evans Hoeker et al., Reproductive Science Sep 2016 2. BCL-6 Overexpression as a Predictor for Endometriosis in Patients Undergoing In Vitro Fertilization. Journal of the society of laparoscopic and robotic surgeons,, C Nezhat, et al. Oct. 2020 3. Positive Predictive Value of Endometiral BCL6 overexpression in patients with Pathology confirmed endometriosis. Rambhatla et al., F&S Apr 2020

What Is Included When You Get Your Results

Your pathology report will provide you with a detailed analysis of your results. The report will include:

  • Diagnosis and interpretation of the MyReceptiva markers ordered.
  • Full pathology analysis of tissue, ruling out malignancy, atypical cells or any other
    concerning issues such as potential infections.
  • Signature of board certified pathologist that reviewed your case.
View a Sample Report

Find a Specialist

There are many specialists that can assist in your follow-up. Your regular doctor can make recommendations for local or regional endometriosis specialists. In addition, the following articles and resources are available through these trusted organizations and can further help you identify experts in your metro area or region of the US.

Biopsy Collection Information for Patients and Providers

The MyReceptivaTM test is based on a timed biopsy 7 to 10 days following the detection of ovulation. For your convenience, every MyReceptivaTM Test Kit order comes with a complimentary home use Ovulation Kit. Once ovulation is detected, your biopsy window opens up 7 to 10 days later. For example, if you detect ovulation with the kit on a Monday, your biopsy window opens the following Monday for 4 days.

Call your provider upon ovulation detection to schedule your biopsy. And don’t forget to bring your collection kit, as most provider offices do not routinely stock the MyReceptivaTM Kit in their office. For further assistance, please download and print these detailed instructions (PDF, opens in a new tab):

collection instructions

Publications

Learn more from studies showing the correlation of a positive BCL6 result to endometriosis or IVF failure.

  • BCL-6 Overexpression as a Predictor for Endometriosis in Patients Undergoing In Vitro Fertilization

    Camran Nezhat, MD, Anupama Rambhatla, MD, Catarina Miranda-Silva, MD, Atena Asiaii, MD, Kimsa Nguyen, BS, Aimee Eyvazzadeh, MD, Salli Tazuke, MD, Shruti Agarwal, DO, Sunny Jun, MD, Azadeh Nezhat, MD, Robert A. Roman, MD

    Summary: The Positive predictive value of the ReceptivaDx™ was 96% confirmed by surgical laparoscopy.

    Read More

  • Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes.

    December 2017

    Laura D. Almquist, M.D., Creighton E. Likes, M.D., Benjamin Stone, B.S., Kaitlin R. Brown, B.S., Ricardo Savaris, M.D., Ph.D., David A. Forstein, D.O., Paul B. Miller, M.D., Bruce A. Lessey, M.D., Ph.D.

    Summary: Demonstrates the predictive value of positive BCL6 results without treatment with poor live birth success

    Read More

  • Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression.

    January 2019

    Creighton E. Likes, Leah J. Cooper, Jessica Efird, David A. Forstein, Paul B. Miller, Ricardo Savaris, Bruce A. Lessey

    Summary: Women with suspected endometriosis and high endometrial BCL6 expression have worse reproductive outcomes following embryo transfer, including a high miscarriage rate and low clinical pregnancy and live birth rates compared to cycles pre-treated with medical and surgical management.

    Read More

  • Clinical approach to recurrent implantation failure: evidence-based evaluation of the endometrium

    April 2019

    Harvey J. Kliman, M.D., Ph.D.a and David Frankfurter, M.D.

    Summary: Highlights the importance of assessing the endometrium as the cause of unexplained implantation failure.

    Read More

  • Unexplained recurrent pregnancy loss and unexplained infertility: twins in disguise.

    October 2019

    Chelsea W Fox, Ricardo F Savaris, Jae-Wook Jeong, Tae Hoon Kim, Paul B Miller, Creighton E Likes, David P Schammel, Steven L Young, Bruce A Lessey

    Summary: Endometrial BCL6 expression is elevated to a similar degree in women with unexplained recurrent pregnancy loss and unexplained infertility compared to fertile controls likely due to endometriosis.

    Read More

  • Outcomes in women with IVF failure who tested positive for BCL6 using ReceptivaDx testing: Effect of treatment on subsequent embryo transfer

    April 2020

    Dan Angress

    Summary: Demonstrates the positive impact of treatment for positive BCL6 patients on live births success.

    Read More

  • Unexplained Euploid Embryo Transfer Failure: Testing and Treatment Options

    March 2024

    Bruce A Lessey MD, PhD1, Allan Dong MD1, David Wininger PhD1, Jeffrey L Deaton MD1, Ricardo Savaris MD, PhD2.

    Summary; Patients who had failed IVF more than once, had their embryos genetically tested and then treated for positive BCL6 had live birth rates comparable to first time transfers for women who had not failed. Positive BCL6 Women who chose not to be treated fared poorly in live birth rates.

    Read More

  • Endometrial BCL6 Overexpression in Eutopic endometrium of women with endometriosis.

    September 2016

    Evans-Hoeker E, Lessey BA, Jeong JW, Savaris RF, Palomino WA, Yuan L, Schammel DP, Young SL.

    Summary: First paper showing role of BCL6 as predictor of endometriosis using an endometrial biopsy.

    Read More

  • KRAS Activation and overexpression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance.

    July 2017

    Jung-Yoon Yoo1,2, Tae Hoon Kim1, Asgerally T. Fazleabas1,3, Wilder A. Palomino4, Soo Hyun Ahn 5, Chandrakant Tayade5, David P. Schammel6, Steven L. Young7, Jae-Wook Jeong1,3 & Bruce A. Lessey8.

    Summary: Endometriosis is an inflammatory condition that is associated with progesterone resistance and cell proliferation, resulting in pain, infertility and pregnancy loss. This study data suggest that KRAS, SIRT1 and BCL6 are coordinately over-expressed in eutopic endometrium of women with endometriosis and likely participate in the pathogenesis of endometriosis.

    Read More

  • BCL6, a key oncogene, in the placenta, pre-eclampsia and endometriosis

    May 2022

    Frank Louwen, Nina-Naomi Kreis, Andreas Ritter, Alexandra Friemel, Christine Solbach, and Juping Yuan

    Summary

    Read More

Take charge of your health.

  • The facts are clear. Endometriosis is missed or overlooked by many physicians.
  • Almost half of women saw 3 to 5 providers before being diagnosed.
  • This is your body and your choice.

  • Asking for the test with a kit in your hands and the facts to support you ensures your doctor will listen to your concerns.

Order Your Collection Kit

Endometriosis affects an estimated 2 to 10% of American women between the ages of 25 and 40, which is why we’re determined to help provide answers and solutions. Millions of women have suffered from endometriosis and have been able to find solutions.

We are here to help.